COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

bioRxiv posts many COVID19-related papers. A reminder: they have not been formally peer-reviewed and should not guide health-related behavior or be reported in the press as conclusive.

29,076 Articles (21,549 medRxiv, 7,527 bioRxiv)

Most recent first Previous |  Page 2668: Articles 26671-26680  | Next

Towards the next phase: evaluation of serological assays for diagnostics and exposure assessment.
GeurtsvanKessel, C. H., OKBA, N. M. A., Igloi, Z., Embregts, C. W. E., Laksono, B. M., Leijten, L., Rahamat-Langendoen, J., van den Akker, J. P. C., van Kampen, J. J. A., van der Eijk, A. A., van Binnendijk, R. S., Hangman, B., Koopmans, M.
10.1101/2020.04.23.20077156 — Posted: 2020-04-29
Role of Drugs Affecting the Renin-Angiotensin-Aldosterone System on Susceptibility and Severity of COVID-19: A Large Case-Control Study from Zheijang Province, China.
Yan, H., Valdes, A. M., Vijay, A., Wang, S., Liang, L., Yang, S., Wang, H., Tan, X., Du, J., Jin, S., Huang, K., Jiang, F., Zhang, S., Zheng, N., Hu, Y., Cai, T., Aithal, G. P.
10.1101/2020.04.24.20077875 — Posted: 2020-04-29
COVID-19 in India: State-wise Analysis and Prediction
Ghosh, P., Ghosh, R., Chakraborty, B.
10.1101/2020.04.24.20077792 — Posted: 2020-04-29
A prototype for decision support tool to help decision-makers with the strategy of handling the COVID-19 UK epidemic
Zhigljavsky, A., Fesenko, I., Wynn, H., Kremnitzer, K., Noonan, J., Gillard, J., Whitaker, R.
10.1101/2020.04.24.20077818 — Posted: 2020-04-29
Influence of socio-ecological factors on COVID-19 risk: a cross-sectional study based on 178 countries/regions worldwide
Su, D., Chen, Y., He, K., Zhang, T., Tan, M., Zhang, Y., Zhang, X.
10.1101/2020.04.23.20077545 — Posted: 2020-04-29
Quantifying early COVID-19 outbreak transmission in South Africa and exploring vaccine efficacy scenarios
Mukandavire, Z., Nyabadza, F., Malunguza, N. J., Cuadros, D. F., Shiri, T., Musuka, G.
10.1101/2020.04.23.20077297 — Posted: 2020-04-29
A Novel Protein Drug, Novaferon, as the Potential Antiviral Drug for COVID-19
Zheng, F., Zhou, Y., Zhou, Z., Ye, F., Huang, B., Huang, Y., Ma, J., Zuo, Q., Tan, X., Xie, J., Niu, P., Wang, W., Xu, Y., Peng, F., Zhou, N., Cai, C., Tang, W., Xiao, X., Li, Y., Zhou, Z., Zhou, Z., Jiang, Y., Xie, Y., Tan, W., Gong, G.
10.1101/2020.04.24.20077735 — Posted: 2020-04-29
Development and potential usefulness of the COVID-19 Ag Respi-Strip diagnostic assay in a pandemic context.
Vandenberg, O.
10.1101/2020.04.24.20077776 — Posted: 2020-04-29
A demographic scaling model for estimating the total number of COVID-19 infections
Bohk-Ewald, C., Dudel, C., Myrskyla, M.
10.1101/2020.04.23.20077719 — Posted: 2020-04-29 Discussion: Onsite
Assessing the community risk perception toward COVID-19 outbreak in South Korea: evidence from Google and NAVER relative search volume
Husnayain, A., Shim, E., Fuad, A., Su, E. C.-Y.
10.1101/2020.04.23.20077552 — Posted: 2020-04-29

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).